GlassScriptPhysician profile
Carol A Salisbury
NPI 1831208776
$7,689.80
in general payments reported to CMS, 2019-2025
21 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,713 · 2022: $965 · 2023: $1,256 · 2024: $1,659 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,012.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,436.10 | 2021-2025 | Yeztugo, Biktarvy |
| Viiv Healthcare Company | $1,666.12 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $866.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $363.41 | 2021-2025 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $254.62 | 2022-2025 | Nuedexta, Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $171.48 | 2025 | Auvelity |
| Novo Nordisk INC | $167.93 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Biotech, INC. | $116.54 | 2021-2023 | Symtuza |
| Janssen Products, LP | $99.95 | 2021 | |
| Lilly USA, LLC | $98.31 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Theratechnologies INC. | $90.08 | 2023 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $71.39 | 2022-2025 | Arexvy |
| Vanda Pharmaceuticals INC. | $66.43 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.08 | 2022-2025 | Caplyta |
| Pfizer INC. | $41.84 | 2023-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $30.18 | 2021-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Abbott Laboratories | $16.06 | 2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $15.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.66 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Salisbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.